Name: | Description: | Size: | Format: | |
---|---|---|---|---|
225.31 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Drugs pertaining to Biopharmaceutics Classification System (BCS) classes II and IV have limitations in their
delivery, including in the lung. Therefore, drug delivery carriers have been proposed to improve the therapeutic
effectiveness of such drugs. This work proposes lipid nanocapsules (LNC) as a potential platform for lung drug
delivery. Locust bean gum (LBG), which is a galactomannan, was used as polymeric shell, protecting the oily core
of the nanocapsules and providing their surface with hydrophilic character. Due to the neutral character of LBG, in
order to enable nanocapsule formation, a sulphate derivative (LBGS) was prepared, which was confirmed by
Fourier-transformed infrared (FTIR) spectroscopy. The electrostatic interaction between the negatively charged
sulphate groups of LBGS and the positively charged groups of the used cationic lipid (1,2-dioleoyloxy-3-
trimethylammoniumpropanchloride, DOTAP), allowed the formation of monodisperse nanocapsules, with sizes
around 200 nm and strongly negative zeta potentials, between -70 and -85 mV. Envisaging potential lung drug
delivery, the LBGS-coated LNC were co-formulated with mannitol using spray-drying, producing microencapsulated
nanocapsules. Feret’s diameter was determined to be 2.6 ± 1.8 µm and 3.1 ± 1.9 µm for Man (control) and Man/LNC
microparticles, respectively. Further studies are underway in order to optimise both the nanoplatform and the dry
powder formulation.
Description
Keywords
Citation
Publisher
Mary Ann Liebert